9 August 2020 – Matterhorn Biosciences AG, a Swiss biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins, has received a financing of USD 30 million from Versant Ventures. It is the most recent company to be launched out of Versant’s Ridgeline Discovery Engine based in Basel, Switzerland.

Walder Wyss advised Versant Ventures in connection with this transaction. The team was led by Alexander Gutmans (Partner, Transaction/M&A & Venture Capital) and Robert von Rosen (Partner, Transaction/M&A & Venture Capital) and included Markus R. Frick (Partner, IP/IT), Jessica Aeschbach Flórez (Senior Associate, Transaction/M&A) and Karina Tschon (Associate Transaction/M&A).